W hat are the indications for closure of a patent foramen ovale (PFO) in an adult? Very few questions in the field of cardiology are as controversial. Disagreement exists about definitive indications for PFO closure under various circumstances. Approximately 25% of all adults have patency of the foramen ovale. This translates to 60 million people in the United States who have this finding. It is estimated that there are 280 000 cryptogenic strokes per year. 1, 2 Patients with cryptogenic stroke have a higher prevalence of PFO than age-and sex-matched controls. 3, 4 Nevertheless, without pathological evidence, definitive proof of the linkage is hard to come by. Statistical associations can be suggestive or even rather convincing, but for the vast majority of patients, absolute evidence is lacking. Catheter interventions for such patients are usually performed at low risk, but are even small risks justified when cause and effect remains unproven? There is extensive literature that attempts to answer this question, but controversy remains.
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Patients who have had a cryptogenic stroke and a PFO are often treated with chronic anticoagulation therapy, and the risk of recurrent events appears to be reduced. 5 Currently, the labeled indication for PFO device closure is recurrent stroke in patients who had an event despite treatment, or are not candidates for anticoagulation. Nevertheless, a considerable number of interventional and general cardiologists are convinced that device closure in the cardiac catheterization laboratory is the most definitive initial management of such patients. PFO interventions for patients with only vague symptoms of possible transient ischemic attacks have few advocates.
Migraine headache is the newest indication for which aggressive management of the PFO has been proposed. Reports have appeared suggesting that a PFO-migraine association exists and that closure of the PFO results in alleviation of symptoms. This concept began when early observational studies reported a beneficial effect of PFO closure on migraine headaches in patients undergoing device closure for a variety of other indications. 6, 7 These findings led to a hypothesis that intermittent right-to-left shunting at the atrial level is involved in the mechanism of migraine, especially migraine with aura. A recent meta-analysis of 11 such studies included 522 patients who had undergone PFO device closure and also had migraine headaches. The patients were followed up for at least 6 months and up to 39 months. Forty-six percent of patients reported that they had been "cured," and 83% reported significant improvement. 8 In addition to the known limitations of systematic reviews, this analysis was limited by retrospective and nonblinded protocols. In the vast majority of cases, the data collected were based on patient recall and not objective, validated questionnaires. These issues increased the likely impact of placebo effect on the reported results. Furthermore, because virtually all patients were treated with antiplatelet agents, which have been independently shown be beneficial to patients with migraine, the effect of device closure becomes even more difficult to interpret.
Because of the clear limitations of the early uncontrolled studies that reported a benefit of PFO device closure on migraine outcome, the Migraine Intervention with STARFlex Technology trial was undertaken. 9 This was a randomized, double-blind, sham-controlled trial. One hundred forty-seven patients with a history of severe migraine headache and without other indications for PFO device closure were randomized to undergo either device closure or a sham procedure. All patients were treated with aspirin and clopidogrel. No significant difference in the primary outcome of headache cessation was detected between the 2 groups. There also was no difference in the secondary outcome of headache frequency or intensity, although when 2 outliers were excluded from the analysis, there was a significant reduction in migraine headache days in the closure group (37%) compared with the sham group (26%). A number of investigators do not consider the Migraine Intervention with STARFlex Technology trial to be definitive. Questions have been raised about the possible impact of incomplete closure of the atrial shunt. 10 In addition, the population was somewhat different from published observational studies in that patients who were included had severe refractory forms of migraine and had no other indication for PFO closure. The possibility has been raised that it is the more mild forms of migraine headache and/or those associated with transient ischemic attack or stroke that may be uniquely impacted by intermittent rightto-left shunting at the atrial level. Despite these concerns, the Migraine Intervention with STARFlex Technology study provided no evidence basis for the use of migraine headache as an indication for device closure of a PFO. Nevertheless, as with so many long-forgotten medical tenets, "letting go" of a medical concept was difficult until the negative evidence was seen by the medical community as unequivocal. Changing medical practice often requires more proof than the studies that led to the practice in the first place. In the present issue of Circulation, an elegant case-control study has explored the possibility of a PFO-migraine association. Garg and associates 11 compared the prevalence of PFO in patients with a well-defined history of migraine diagnosed by neurologists in an academic specialty clinic with that of age-and sex-matched control subjects. Documentation of the presence of a PFO was determined by infusion of agitated saline contrast with and without the Valsalva maneuver during transthoracic imaging and transcranial Doppler. The echocardiographers were blinded as to the status of the individual patients. One hundred forty-four cases were studied in each group. The authors found "no association between migraine headaches and the presence of PFO." In addition, there was no association between migraine headache and severity of shunt across the PFO nor the presence of aura. These findings are consistent with a population-based study by Rundek and colleagues that evaluated more than 1000 healthy volunteers. 12 The authors found no difference in the prevalence of PFO between patients with and without migraine headaches. 12 In published reports, proponents of PFO intervention for migraine acknowledge that the grade of evidence has been far from definitive. Apparent improvement in the number of or severity of migraine headaches after PFO closure may have a number of other possible explanations, including placebo effect. The results of the study by Garg et al 11 are evidence based at the highest level and clearly refute the PFO-migraine association.
Migraine headaches cause tremendous suffering and moderate to severe disability for more than 10 million people in the United States. 13 Clearly, it would very beneficial if a relatively low-risk procedure performed in the cardiac catheterization laboratory resulted in widespread patient relief and improved functioning. Unfortunately, the present body of evidence does not support this scenario. Although in rare instances, exceptions may be proposed, closure of a PFO for migraine should not be considered standard medical practice. It is important that the medical community becomes fully aware of the strength of the negative evidence. Despite any lingering unresolved issues, all physicians can agree with the concluding statement by Garg and associates that investigation of the mechanisms of migraine is the key to future approaches to prevention and alleviation of migraine symptoms. 11
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